139A. In regulation 179—
(a)in paragraph (1), after “pharmacovigilance system” insert “in relation to medicinal products for sale or supply in Great Britain”;
(b)after paragraph (1) insert—
“(1A) The licensing authority must operate a pharmacovigilance system in relation to medicinal products for sale or supply in Northern Ireland.”;
(c)in paragraph (2) for “The pharmacovigilance system” substitute “Each pharmacovigilance system”; and
(d)in paragraph (3)(a) for “the pharmacovigilance system” substitute “each pharmacovigilance system”.]
Textual Amendments
F1Reg. 139A inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 108
Commencement Information
I1Reg. 139A in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1